source
- Ionis secures FDA approval for zilganersen, its first solo neurology therapy for Alexander diseaseIonis Pharmaceuticals announced that the U.S. Food and Drug Administration has granted approval to its investigational RNA‑based drug zilganersen for the treatment of Alexander disease, a rare neur…
- NeuShen Therapeutics raises over $80 million to advance three brain-health drug candidatesNeuShen Therapeutics, a biotech with operations in Shanghai and Boston, announced it has closed a Series B financing round of more than $80 million. The capital will be used to move three clinical…